

CLAIMS

1. A pharmaceutical formulation comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents, selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6, and a pharmaceutically acceptable excipient.

2. A nutritional formulation in the dosage form of a hard or soft gelatin capsule comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.

3. A pharmaceutical or nutritional formulation comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6, the formulation comprising 200 µg or more of the one or more homocysteine-lowering agents.

4. A formulation according to <sup>claim 1</sup> ~~any preceding claim~~ in which the EFA is eicosapentaenoic acid (EPA).

5. A formulation according to <sup>claim 1</sup> ~~any of claims 1-3~~ in which the EFA is eicosapentaenoic acid (EPA) in the form of the ethyl ester or of the pure tri-EPA triglyceride.

6. A formulation according to <sup>claim 1</sup> ~~any of claims 1-3~~ in which the EFA is arachidonic acid.

claim 1  
7. A formulation according to ~~any of claims 1-3~~ in which the EFA is gammalinolenic acid or dihomogammalinolenic acid.

claim 1  
5 8. A formulation according to ~~any of claims 1 to 3~~ in which the EFA is docosaheanoic acid.

claim 1  
9. A formulation according to ~~any preceding claim~~ comprising two or more EFAs.

claim 1  
10 10. A formulation according to ~~any preceding claim~~ comprising at least 5% EFA, preferably more than 15% EFA, very preferably more than 30%, more then 50%, more than 90% or more than 95% EFA.

claim 1  
15 11. A formulation according to ~~any preceding claim~~ comprising vitamin B12, preferably in the form of hydroxocobalamin, as the only homocysteine-lowering agent.

claim 1  
20 12. A formulation according to ~~any of claims 1 - 10~~ comprising folic acid or a related compound with similar biological activity as the only homocysteine-lowering agent.

claim 1  
25 13. A formulation according to ~~any preceding claim~~ in a form suitable for oral administration.

claim 1  
30 14. A formulation according to ~~any preceding claim~~ further comprising one or more antioxidants selected from natural, synthetic or semi-synthetic forms of vitamin E, coenzyme Q, alpha-lipoic acid and vitamin C.

0046736 074300

1. The first part of the paper is devoted to the study of the asymptotic behavior of the solutions of the system (1) as  $t \rightarrow \infty$ . It is shown that the solutions of the system (1) are bounded and tend to zero as  $t \rightarrow \infty$ .

- a. Any illness;
- b. Any cardiovascular or cerebrovascular disorder, including any form of atherosclerosis of the coronary, cerebral or peripheral blood vessels, any form of heart disease, any form of cerebrovascular disease or stroke, any form of peripheral vascular disease and any form of thrombosis;
- c. Any form of diabetes or pre-diabetes (syndrome X) and any of the macro- or microvascular complications of diabetes including cardiovascular disease, retinopathy, nephropathy or neuropathy;
- d. Any form of psychiatric disorder including schizophrenia, schizotypal disorder and other schizophreniform disorders, bipolar disorder (mania, or manic depression), depression of any form, and panic or anxiety disorders, sleep disorders and social phobias;
- e. Any form of neurological or neurodegenerative disorder including Alzheimer's disease and other forms of dementia, Parkinson's disease, multiple sclerosis, Huntington's disease and any form of chronic pain;
- f. Any form of kidney disorder;
- g. Any form of inflammatory or immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or any other tissues;

- form of eye or hearing  
related macular degene  
ss, or tinnitus;  
form of obesity, and  
of treatment of ob  
form of cancer.

add

add E<sup>e</sup>